<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37128299</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Antihistamines as an early treatment for Covid-19.</ArticleTitle><Pagination><StartPage>e15772</StartPage><MedlinePgn>e15772</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15772</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2023.e15772</ELocationID><Abstract><AbstractText>Infection with SARs-COV-2 results in COVID-19 disease. Between March 2020 and August 2021, 468 COVID-19 patients confirmed by PCR or antigen test, in Yepes, Spain, received early treatment with antihistamines, adding azithromycin in selected cases. The primary endpoint is the hospitalization rate of COVID-19 patients, and the secondary endpoints are ICU admission and mortality rates. All endpoints are compared with the official Spanish rates during the time period of the study. There were 20 hospital admissions (hospitalization rate 4,3%), 5 ICU admissions (ICU admission rate 1,1%) and 3 deaths (fatality rate of 0,6%). No patients in the study required follow up treatment, which suggest they did not develop long COVID. Results from this retrospective trail indicate that early treatment of SARS-COV-2 positive patients with antihistamines may reduce the odds of hospitalization (OR: 0.490, CI: 0.313-0.767, p-value: 0.001). Randomized controlled clinical trials are needed to further evaluate the effects of early antihistamine treatment of SARS-CoV-2 patients to prevent hospitalization, ICU admission, mortality and long-covid.</AbstractText><CopyrightInformation>&#xa9; 2023 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mor&#xe1;n Blanco</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Salud de Yepes, Toledo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarenga Bonilla</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Salud de Yepes, Toledo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fremont-Smith</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Massachusetts Institute of Technology Lincoln Laboratory, Lexington, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villar G&#xf3;mez de Las Heras</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerencia de Urgencias, Emergencias y Transporte Sanitario, Toledo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Alcal&#xe1; de Henares, Facultad de Medicina y Ciencias de la Salud, Alcal&#xe1; de Henares, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihistamines</Keyword><Keyword MajorTopicYN="N">Azithromycin</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37128299</ArticleId><ArticleId IdType="pmc">PMC10129342</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2023.e15772</ArticleId><ArticleId IdType="pii">S2405-8440(23)02979-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cataldi M., Maurer M., Taglialatela M., Church M.K. Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria. Clin. Exp. Allergy. 2019;49(12):1615&#x2013;1623. doi: 10.1111/cea.13500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13500</ArticleId><ArticleId IdType="pubmed">31519068</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone R.W., Tisdall P., Fremont-Smith P., et al. COVID-19: famotidine, histamine, mast cells, and mechanisms. Front. Pharmacol. 2021;12(March:1&#x2013;21. doi: 10.3389/fphar.2021.633680.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.633680</ArticleId><ArticleId IdType="pmc">PMC8021898</ArticleId><ArticleId IdType="pubmed">33833683</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100(January):327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P., Caraffa A., Tet&#xe8; G., et al. Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19. J. Biol. Regul. Homeost. Agents. 2020;34(5):1629&#x2013;1632. doi: 10.23812/20-2EDIT.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-2EDIT</ArticleId><ArticleId IdType="pubmed">32945158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricke D.O. Hyperactivated mast cells pathogenesis hypothesis for COVID-19 cutaneous manifestations. JID Innov. 2021;1(4) doi: 10.1016/j.xjidi.2021.100052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xjidi.2021.100052</ArticleId><ArticleId IdType="pmc">PMC8381631</ArticleId><ArticleId IdType="pubmed">34458884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan R.B., Hogan R.B., Cannon T., et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Puml. Pharm. Ther, 2020;63 (January)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455799</ArticleId><ArticleId IdType="pubmed">32871242</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco Ji Mor&#xe1;n, Alvarenga Bonilla J.A., Homma S., Suzuki K., Fremont-Smith P., G&#xf3;mez de las Heras K.V. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care &#x2013; a retrospective observational study in elderly patients. Pulm. Pharmacol. Ther. 2021 doi: 10.1016/j.pupt.2021.101989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2021.101989</ArticleId><ArticleId IdType="pmc">PMC7833340</ArticleId><ArticleId IdType="pubmed">33465426</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Potential association of mast cells with coronavirus disease 2019. Ann. Allergy Asthma Immunol. 2021;126(January):217&#x2013;218. doi: 10.1016/j.anai.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7644430</ArticleId><ArticleId IdType="pubmed">33161155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.W., Kanegasaki S., Jin F., et al. A common signaling pathway leading to degranulation in mast cells and its regulation by CCR1-ligand. Allergy Eur. J. Allergy Clin. Immu. 2020;75(6):1371&#x2013;1381. doi: 10.1111/all.14186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14186</ArticleId><ArticleId IdType="pubmed">31954080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; what we know so far. Front. Immunol. 2020;11(June:1&#x2013;4. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin S., Aydin S. 2020. Could Antihistamines Help in the Treatment and Spread of COVID-19 Via Re-Modulating Cytokines and by Reducing Sneezing ? pp. 172&#x2013;173. 4(4)</Citation></Reference><Reference><Citation>Eldanasory O.A., Eljaaly K., Memish Z.A., Al-Tawfiq J.A. Travel Med Infect Dis; 2020;37(August. Histamine Release Theory and Roles of Antihistamine in the Treatment of Cytokines Storm of COVID-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101874</ArticleId><ArticleId IdType="pmc">PMC7470786</ArticleId><ArticleId IdType="pubmed">32891724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosch A., Borgmann S., Rihoux J.-P., K&#xf6;nig W. Effect of the H1 receptor antagonist cetirizine on the stimulated expression of adhesion molecules and the activation of NF&#x3ba;B in human endothelial cells. Int. Arch. Allergy Immunol. 2001;124(1&#x2013;3):362&#x2013;364. doi: 10.1159/000053758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000053758</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold R., Rihoux J.P., K&#xf6;nig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549) Clin. Exp. Allergy. 1999;29(12):1681&#x2013;1691. doi: 10.1046/j.1365-2222.1999.00630.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2222.1999.00630.x</ArticleId><ArticleId IdType="pubmed">10594545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kricker J.A., Page C.P., Gardarsson F.R., Baldursson O., Gudjonsson T., Parnham M.J. Nonantimicrobial actions of macrolides: overview and perspectives for future development. Pharmacol. Rev. 2021;73(4):233&#x2013;262. doi: 10.1124/pharmrev.121.000300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.121.000300</ArticleId><ArticleId IdType="pubmed">34716226</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel M., Akbarshahi H., Bjermer L., Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci. Rep. 2016;6(June:1&#x2013;11. doi: 10.1038/srep28698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28698</ArticleId><ArticleId IdType="pmc">PMC4923851</ArticleId><ArticleId IdType="pubmed">27350308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Xia S., Zou P., Lu L. Erythromycin estolate inhibits zika virus infection by blocking viral entry as a viral inactivator. Viruses. 2019;11(11) doi: 10.3390/v11111064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11111064</ArticleId><ArticleId IdType="pmc">PMC6893414</ArticleId><ArticleId IdType="pubmed">31731598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohe M., Shida H., Jodo S., et al. Macrolide treatment for COVID-19: will this be the way forward? Biosci. Trends. 2020:4&#x2013;5. doi: 10.5582/bst.2020.03058.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2020.03058</ArticleId><ArticleId IdType="pubmed">32249257</ArticleId></ArticleIdList></Reference><Reference><Citation>Homolak J., Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int. J. Antimicrob. Agents. 2020;(xxxx) doi: 10.1016/j.ijantimicag.2020.106044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106044</ArticleId><ArticleId IdType="pmc">PMC7275137</ArticleId><ArticleId IdType="pubmed">32522674</ArticleId></ArticleIdList></Reference><Reference><Citation>Damle B., Vourvahis M., Wang E., Leaney J., Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin. Pharmacol. Ther. 2020;0(0):1&#x2013;11. doi: 10.1002/cpt.1857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1857</ArticleId><ArticleId IdType="pmc">PMC7262099</ArticleId><ArticleId IdType="pubmed">32302411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherrmann J. Intracellular ABCB1 as a possible mechanism to explain the synergistic effect of hydroxychloroquine-azithromycin combination in COVID-19 therapy. AAPS J. 2020;22(4):1&#x2013;6. doi: 10.1208/s12248-020-00465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-020-00465-w</ArticleId><ArticleId IdType="pmc">PMC7291928</ArticleId><ArticleId IdType="pubmed">32533263</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;garbane B., Scherrmann J.M. Hydroxychloroquine and azithromycin to treat patients with COVID-19: both friends and foes? J. Clin. Pharmacol. 2020;60(7):808&#x2013;814. doi: 10.1002/jcph.1646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1646</ArticleId><ArticleId IdType="pmc">PMC7280673</ArticleId><ArticleId IdType="pubmed">32434282</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy B.S., Sundareshan V., Cory T.J., Hayes D., Anstead M.I., Feola D.J. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 2008;61(3):554&#x2013;560. doi: 10.1093/jac/dkn007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkn007</ArticleId><ArticleId IdType="pubmed">18230686</ArticleId></ArticleIdList></Reference><Reference><Citation>Touret F., Gilles M., Barral K., et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 2020;10(1):1&#x2013;8. doi: 10.1038/s41598-020-70143-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70143-6</ArticleId><ArticleId IdType="pmc">PMC7403393</ArticleId><ArticleId IdType="pubmed">32753646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaya M., Shinya K., Hatachi Y., et al. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. J. Pharmacol. Exp. Therapeut. 2010;333(1):81&#x2013;90. doi: 10.1124/jpet.109.162149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.162149</ArticleId><ArticleId IdType="pubmed">20040578</ArticleId></ArticleIdList></Reference><Reference><Citation>Min J.Y., Jang Y.J. Macrolide therapy in respiratory viral infections. Mediat. Inflamm. 2012;2012 doi: 10.1155/2012/649570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/649570</ArticleId><ArticleId IdType="pmc">PMC3375106</ArticleId><ArticleId IdType="pubmed">22719178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondejar-Lopez P., Quintana-Gallego E., Giron-Moreno R.M., et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: incidence and results of the national CF-COVID19-Spain survey. Respir. Med. 2020;170(May) doi: 10.1016/j.rmed.2020.106062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106062</ArticleId><ArticleId IdType="pmc">PMC7831988</ArticleId><ArticleId IdType="pubmed">32843180</ArticleId></ArticleIdList></Reference><Reference><Citation>European Cystic Fibrosis Society  . 2021. COVID-19 in People with CF in Europe. Data up to 15 Nov 2021.https://www.ecfs.eu/covid-cf-project-europe Published.</Citation></Reference><Reference><Citation>Butler C.C., Dorward J., Yu L.M., et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063&#x2013;1074. doi: 10.1016/S0140-6736(21)00461-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00461-X</ArticleId><ArticleId IdType="pmc">PMC7972318</ArticleId><ArticleId IdType="pubmed">33676597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinks T.S.C., Cureton L., Knight R., et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir. Med. 2021;9(10):1130&#x2013;1140. doi: 10.1016/S2213-2600(21)00263-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00263-0</ArticleId><ArticleId IdType="pmc">PMC8270523</ArticleId><ArticleId IdType="pubmed">34252378</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado R.H.M., Berwanger O., Fonseca H.A., et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959&#x2013;967. doi: 10.1016/S0140-6736(20)31862-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31862-6</ArticleId><ArticleId IdType="pmc">PMC7836431</ArticleId><ArticleId IdType="pubmed">32896292</ArticleId></ArticleIdList></Reference><Reference><Citation>Million M., Lagier J.C., Tissot-Dupont H., et al. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Rev. Cardiovasc. Med. 2021;22(3):1063&#x2013;1072. doi: 10.31083/J.RCM2203116.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/J.RCM2203116</ArticleId><ArticleId IdType="pubmed">34565108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashad A., Nafady A., Hassan M.H., et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci. Rep. 2021;11(1):1&#x2013;7. doi: 10.1038/s41598-021-95900-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95900-z</ArticleId><ArticleId IdType="pmc">PMC8357809</ArticleId><ArticleId IdType="pubmed">34381155</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekhavati E., Jafari F., Seyedalinaghi S., et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int. J. Antimicrob. Agents. 2020;56(January</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445147</ArticleId><ArticleId IdType="pubmed">32853672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P., Lagier J.-C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;(xxxx) doi: 10.1016/j.ijantimicag.2020.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz R.A., Suskind R.M. Azithromycin and COVID-19: prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol. Ther. 2020;33(4):2&#x2013;4. doi: 10.1111/dth.13785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13785</ArticleId><ArticleId IdType="pmc">PMC7300563</ArticleId><ArticleId IdType="pubmed">32510734</ArticleId></ArticleIdList></Reference><Reference><Citation>Centro Nacional de Epidemiolog&#xed;a - instituto de Salud Carlos III - ministerio de Sanidad. COVID-19 en Espa&#xf1;a. 2022. https://cnecovid.isciii.es/covid19/#documentaci&#xf3;n-y-datos Published.</Citation></Reference><Reference><Citation>Datadista. No title. https://github-com.translate.goog/datadista/datasets?_x_tr_sl=es&amp;_x_tr_tl=en&amp;_x_tr_hl=en&amp;_x_tr_pto=op (wapp)</Citation></Reference><Reference><Citation>Maci&#xe1;-Mart&#xed;nez M.-A., Gil M., Huerta C., et al. Base de Datos para la Investigaci&#xf3;n Farmacoepidemiol&#xf3;gica en Atenci&#xf3;n Primaria (BIFAP): a data resource for pharmacoepidemiology in Spain. Pharmacoepidemiol. Drug Saf. 2020;29(10):1236&#x2013;1245. doi: 10.1002/pds.5006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5006</ArticleId><ArticleId IdType="pubmed">32337840</ArticleId></ArticleIdList></Reference><Reference><Citation>General de Sanidad Secretaria. Actualizaci&#xf3;n No524. Enfermedad Por El Coronavirus (COVID-19). 16.12.2021 - Centro de Coordinaci&#xf3;n de Alertas y Emergencias Sanitarias. 2021. http://www.Sanidad.Gob.Es/Profesionales/SaludPublica/Ccayes/AlertasActual/NCov/Documentos/Actualizacion_524_COVID-19https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_44_COVID_1200.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>